PAVmed (PAVM) Projected to Post Quarterly Earnings on Friday

PAVmed (NASDAQ:PAVM) is anticipated to announce its Q1 2026 results after the market closes on Friday, May 15th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $0.0740 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 8:30 AM ET.

PAVmed Price Performance

NASDAQ:PAVM opened at $6.50 on Wednesday. The firm has a 50-day moving average of $9.37 and a 200-day moving average of $9.67. The company has a market cap of $6.50 million, a PE ratio of -0.29 and a beta of 0.64. PAVmed has a one year low of $6.00 and a one year high of $28.44.

Wall Street Analyst Weigh In

PAVM has been the topic of several analyst reports. Ascendiant Capital Markets cut their price target on shares of PAVmed from $510.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. Wall Street Zen upgraded shares of PAVmed from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of PAVmed in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $65.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC raised its stake in PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the quarter. Jane Street Group LLC owned approximately 0.31% of PAVmed worth $32,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 19.93% of the company’s stock.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.